Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹73,704 Cr
Revenue (TTM)
₹33,182 Cr
Net Profit (TTM)
₹3,487 Cr
ROE
11.1 %
ROCE
14.4 %
P/E Ratio
21.1
P/B Ratio
2.1
Industry P/E
29.25
EV/EBITDA
9.8
Div. Yield
0 %
Debt to Equity
0.2
Book Value
₹619
EPS
₹60.8
Face value
1
Shares outstanding
580,801,623
CFO
₹29,776.53 Cr
EBITDA
₹45,072.77 Cr
Net Profit
₹28,517.00 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
| 7.3 | 6.9 | 6.4 | 14.1 | 38.5 | 8.6 | 5.7 |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
| -12.6 | 23.5 | 147.3 | -40.3 | -20.8 | 101.1 | -37.7 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
|
1,269.0 | 73,703.7 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.1 | 2.1 |
| 26,375.0 | 55,882.2 | 6,824.1 | 1,524.1 | 25.9 | 37 | 36.7 | 12.7 | |
| 5,351.5 | 63,950.5 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27 | 4.6 | |
| 382.6 | 61,967.3 | 16,827.4 | 629.6 | 9.6 | -0.1 | 102.6 | 1.6 | |
| 2,437.6 | 41,252.1 | 3,800.7 | 1,021.0 | 32.2 | 55 | 40.4 | 20.6 | |
| 1,543.6 | 39,123.7 | 9,504.5 | 947.8 | 15.9 | 14.6 | 43 | 5.0 | |
| 2,302.4 | 1,05,236.5 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.7 | 5.1 | |
| 2,103.1 | 86,793.0 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 48.8 | 5.5 | |
| 1,778.3 | 4,26,781.7 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.1 | 5.3 | |
| 899.6 | 90,435.3 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.3 | 3.4 |
6 min read•By Yash Rohra
4 min read•By Jugal Harpalani
1 min read•By Research Desk
2 min read•By Mohammed Ekramul Haque
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers... formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India. Read more
Incorporated
1986
Chairman
Mangalam Ramasubramanian Kumar
Managing Director
K Nityananda Reddy
Group
Aurobindo
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Aurobindo Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Aurobindo Pharma Ltd is ₹1,269.00 (NSE) and ₹1,269.00 (BSE) as of 18-Mar-2026 IST. Aurobindo Pharma Ltd has given a return of 38.49% in the last 3 years.
The P/E ratio of Aurobindo Pharma Ltd is 21.14 times as on 18-Mar-2026, a 28 discount to its peers’ median range of 29.25 times.
The P/B ratio of Aurobindo Pharma Ltd is 2.05 times as on 18-Mar-2026, a 55 discount to its peers’ median range of 4.56 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.32
|
2.06
|
|
2024
|
20.12
|
2.14
|
|
2023
|
15.75
|
1.13
|
|
2022
|
14.80
|
1.59
|
|
2021
|
9.68
|
2.36
|
The 52-week high and low of Aurobindo Pharma Ltd are Rs 1,319.80 and Rs 1,010.00 as of 18-Mar-2026.
Aurobindo Pharma Ltd has a market capitalisation of ₹ 73,704 Cr as on 18-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Aurobindo Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-17.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.